COLUMBIA, Mo.--(BUSINESS WIRE)--Endevica Bio, a company developing best-in-class peptide drug candidates with better safety and efficacy properties, presented new data from a recent preclinical study ...
Altimmune, Inc. shares surged nearly 30% after positive Phase 2 clinical study results for pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Pemvidutide may compete with Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results